Persistent high-risk human papillomavirus infections and other end-point markers of progressive cervical disease among women prospectively followed up in the new independent states of the former soviet union and the latin american screening study cohorts

International Journal of Gynecological Cancer

Volumn 19, Issue 5, 2009, Pages 934-942

  Syrjänen, Kari ^a   Shabalova, Irena ^b   Naud, Paulo ^c,d   Kozachenko, Vladimir ^b   Derchain, Sophie ^e   Zakharchenko, Sergej ^f   Roteli Martins, Cecilia ^g   Nerovjna, Raisa ^h   Longatto Filho, Adhemar ^i,j   Kljukina, Ludmila ^k   Tatti, Silvio ^l   Branovskaja, Marina ^m   Hammes, Luciano Serpa ^c,d   Branca, Margherita ⁿ   Grunjberga, Valerija ^o,p   Eržen, Mojca ^q   Sarian, Luis Otavio ^e   Juschenko, Anna ^o,p   Costa, Silvano ^r   Podistov, Jurij ^s   Syrjänen, Stina ^t   more..

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b Russian Academy of Post Graduate Medical Education   (Russian Federation)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^d FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^e UNIVERSITY OF CAMPINAS   (Brazil)

^f Novgorod Municipal Dermato venereological Dispensary ^*  (Russian Federation)

^g HOSPITAL MATERNIDADE LEONOR MENDES DE BARROS   (Brazil)

^h Novgorod Female Consultative Outpatient Hospital   (Russian Federation)

ⁱ INSTITUTO ADOLFO LUTZ   (Brazil)

^j UNIVERSITY OF MINHO   (Portugal)

^k Research Institute of Oncology and Medical Radiology of the Ministry of Health of the Byelorussian SSR   (Belarus)

^l HOSPITAL DE CLÍNICAS JOSÉ DE SAN MARTÍN   (Argentina)

^m BELARUSIAN STATE MEDICAL UNIVERSITY   (Belarus)

ⁿ ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^o Latvian Cancer Centre   (Latvia)

^p Laboratory of Cytology   (Latvia)

^q SIZE Diagnostic Center   (Slovenia)

^r UNIVERSITY OF BOLOGNA   (Italy)

^s N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^t UNIVERSITY OF TURKU   (Finland)

more..

Author keywords

Cervical infections; HPV; Intermediate end points; LAMS study; NIS cohort; Progression; Prospective follow up

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER SCREENING; CLINICAL TRIAL; CONDYLOMA ACUMINATUM; CONTROLLED STUDY; COURSE EVALUATION; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRIORITY JOURNAL; SOUTH AND CENTRAL AMERICA; USSR; UTERINE CERVIX CARCINOMA IN SITU; VIRUS CARCINOGENESIS; VIRUS DIAGNOSIS; WART VIRUS; ADENOCARCINOMA; COHORT ANALYSIS; GENETICS; GENOTYPE; INTERNATIONAL COOPERATION; MIDDLE AGED; MULTICENTER STUDY; PAPILLOMA VIRUS; PROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX; UTERINE CERVIX TUMOR; VAGINA SMEAR; VIROLOGY; VIRUS INFECTION;

VIRUS DNA;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; CERVIX UTERI; COHORT STUDIES; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INTERNATIONAL AGENCIES; LATIN AMERICA; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; USSR; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS; YOUNG ADULT;

EID: 69449107208     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a834fe     Document Type: Article

References (50)

1. Syrjänen K, Gissmann L, Koss LG, eds. Papillomaviruses and Human Disease. Heidelberg, Germany: Springer Verlag; 1987:1-518.
2. Burk RD, Kelly P, Feldman J, et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis. 1996;23:333-341.
3. Kjaer SK, van den Brule AJ, Bock JE, et al. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiol Biomarkers Prev. 1997;6:799-805.
4. Melkert PW, Hopman E, van den Brule AJ, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer. 1993;53: 919-923.
5. Syrjänen K. Natural history of cervical HPV infections and CIN. Chapter 6. In: Syrjänen K and Syrjänen S, eds. Papillomavirus Infections in Human Pathology. J. Wiley & Sons: New York, NY; 2000:142-166.
6. Herrero R, Hildesheim A, Bratti C, et al. Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst. 2000;92:464-474.
7. Winer RL, Lee SK, Hughes JP, et al. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157:218-226.
8. Syrjänen S, Shabalova IP, Petrovichev N, et al. Acquisition of incident high-risk human papillomavirus (HPV) DNA and PAP smear abnormalities in a cohort of women subjected to HPV screening in the New Independent States (NIS) of the Former Soviet Union. J Clin Microbiol. 2004;42:505-511.
9. Hildesheim A, Schiffman MH, Gravitt PE, et al. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis. 1994;169:235-240.
10. Syrjänen S, Shabalova IP, Petrovichev N, et al. Clearance of high-risk human papillomavirus (HPV) DNA and PAP smear abnormalities in a cohort of women subjected to HPV screening in the New Independent States (NIS) of the Former Soviet Union. Eur J Obstet Gynecol Reprod Biol. 2005;119:219-227. (Pubitemid 40460386)
11. Syrjänen S, Shabalova IP, Petrovichev N, et al. Age-specific incidence and clearance rates of high-risk human papillomavirus (HPV) infections in women subjected to HPV screening in the new independent states. Int J STD AIDS. 2005;16:217-233.
12. Dalstein V, Riethmuller D, Pretet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer. 2003;106: 396-403.
13. Brummer O, Hollwitz B, Bohmer G, et al. Human papillomavirus-type persistence patterns predict the clinical outcome of cervical intraepithelial neoplasia. Gynecol Oncol. 2006;102:517-522.
14. Syrjänen S, Shabalova IP, Petrovichev N, et al. Factors predicting persistence of high-risk human papillomavirus (HPV) infections in women prospectively followed-up in three New Independent States (NIS) of the Former Soviet Union. Eur J Gynaecol Oncol. 2005;26: 491-498. (Pubitemid 41585929)
15. Schiffman M, Herrero R, DeSalle R, et al. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology. 2005; 337:76-84.
16. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet. 2007;370:890-907.
17. Castle PE, Schiffman M, Herrero R, et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis. 2005;191:1808-1816.
18. Syrjänen KJ, Kulmala S-M, Shabalova IP, et al. Epidemiological, clinical and viral determinants of the increased prevalence of high-risk human papillomavirus (HPV) infections in elderly women. Eur J Gynecol Oncol. 2008;29:114-122.
19. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247-1255.
20. Plummer M, Schiffman M, Castle PE, et al. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195: 1582-1589.
21. Kjaer SK, van den Brule AJ, Paull G, et al. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ. 2002;325:572.
22. Kjaer S, Hogdall E, Frederiksen K, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res. 2006;66: 10630-10636.
23. Khan MJ, Castle PE, Lorincz AT, et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005;97:1072-1079.
24. Winer RL, Kiviat NB, Hughes JP, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005; 191:731-738.
25. Castle PE, Solomon D, Schiffman M, et al. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst. 2005;97:1066-1071.
26. Syrjänen S, Shabalova IP, Petrovichev N, et al. Human papillomavirus testing and conventional PAP smear cytology as optional screening tools of women at different risk for cervical cancer in countries of former Soviet Union. J Low Genit Tract Dis. 2002;6:97-110.
27. Syrjänen K, Naud P, Derchain SM, et al. Comparing PAP smear cytology, aided visual inspection, screening colposcopy, cervicography and HPV testing as optional screening tools in Latin America. Study design and baseline data of the LAMS Study. Anticancer Res. 2005;25: 3469-3480.
28. Longatto-Filho A, Maeda MYS, Er°en M, et al. Conventional PAP smear and liquid-based cytology as screening tools in low-resource settings of Latin America. Experience of the Latin American Screening study. Acta Cytol. 2005;49:500-506.
29. Sarian L, Derchain SM, Naud P, et al. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI) cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin American Screening) study. J Med Screen. 2005;12:142-149.
30. Longatto-Filho A, Er°en M, Branca M, et al. Human papillomavirus (HPV) testing as an optional screening tool in low-resource settings of Latin America. Experience from the LAMS Study. Int J Gynecol Cancer. 2006;16:955-962.
31. Hammes LS, Naud P, Passos E, et al. Value of the International Federation of Colposcopy and Cervical Pathology (IFCPC) terminology in predicting cervical pathology. J Low Genit Tract Dis. 2007;11: 158-165.
32. Moberg M, Gustavsson I, Gyllensten U. Real-time PCR-based system for quantification of human papillomavirus types associated with high risk of cervical cancer. J Clin Microbiol. 2003;41:3221-3228.
33. Peitsaro P, Johansson B, Syrjänen S. Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol. 2002;40:886-891.
34. Kulmala SM, Syrjänen SM, Gyllensten UB, et al. Early integration of high copy HPV16 detectable in women with normal and low grade cervical cytology and histology. J Clin Pathol. 2006;59:513-517.
35. Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis. 1999;180: 1415-1423.
36. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327:1272-1288.
37. Moscicki AB, Shiboski S, Broering J, et al. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998;132:277-284.
38. Liaw KL, Glass AG, Manos MM, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst. 1999;91: 954-960.
39. Wallin KL, Wiklund F, Angstrom T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med. 1999;341:1633-1638.
40. Beskow AH, Josefsson AM, Gyllensten UB. HLA class II alleles associated with infection by HPV16 in cervical cancer in situ. Int J Cancer. 2001;93:817-822.
41. ter Harmsel B, Smedts F, Kuijpers J, et al. Relationship between human papillomavirus type 16 in the cervix and intraepithelial neoplasia. Obstet Gynecol. 1999;93:46-50.
42. Bory JP, Cucherousset J, Lorenzato M, et al. Recurrent human papillomavirus infection detected with the hybrid capture II assay selects women with normal cervical smears at risk for developing high grade cervical lesions: a longitudinal study of 3, 091 women. Int J Cancer. 2002;102:519-525.
43. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362:1871-1876.
44. Harris TG, Kulasingam SL, Kiviat NB, et al. Cigarette smoking, oncogenic human papillomavirus, Ki-67 antigen, and cervical intraepithelial neoplasia. Am J Epidemiol. 2004;159:834-842.
45. Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA. 2001;286:3106-3114.
46. Moberg M, Gustavsson I, Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer. 2004;112:854-859.
47. Bais AG, Rebolj M, Snijders PJ, et al. Triage using HPV-testing in persistent borderline and mildly dyskaryotic smears: proposal for new guidelines. Int J Cancer. 2005;116:122-129.
48. Cuschieri KS, Cubie HA, Whitley MW, et al. Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study. J Clin Pathol. 2005;58:946-950.
49. Gontijo RC, Derchain SF, Roteli-Martins C, et al. Human papillomavirus (HPV) infections as risk factors for cytological and histological abnormalities in baseline PAP smear-negative women followed-up for 2 years in the LAMS study. Eur J Obstet Gynecol Reprod Biol. 2007;133:239-246.
50. Woodman CBJ, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer. 2007;7:11-22.